Bausch Health Canada unit Siliq wins Alberta public drug plan reimbursement
BHC•Alberta reimbursement expands Canadian coverage
Bausch Health subsidiary Bausch Health, Canada said SILIQ (brodalumab) gained reimbursement under Alberta’s public drug plan.
The decision expands public coverage for the plaque psoriasis drug in Canada, leaving British Columbia as the only province without public reimbursement.
SILIQ is indicated for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
